Dapansutrile
Small moleculeexperimental
Clinical trial activity
12 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01636141)
Timeline
Indications
Studied for
- Arthralgia · Phase 2/Phase 3
- Arthritis · Phase 2/Phase 3
- Arthritis, Gouty · Phase 2/Phase 3
- COVID-19 · Phase 2
- Cytokine Release Syndrome · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Gout · Phase 2/Phase 3
- Healthy Volunteers · Phase 1
- Heart Failure, Systolic · Phase 1
- Melanoma · Phase 1/Phase 2
- Myocardial Infarction · Early Phase 1
- Osteoarthritis · Phase 2
- Osteoarthritis, Knee · Phase 2
- Pain · Phase 2
- Parkinson Disease · Phase 2
- Schnitzler Syndrome · Phase 2
Mechanism of action
NLRP3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)CCC#N- Mol. weight
- 133.17 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989943 ↗
Also known as
- olt1177
- olt1177
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07157735 | Phase 2 | Nov 30, 2025 | Cure Parkinson's Trust, Olatec Industries LLC, University of Cambridge, Van Andel Research Institute |
| NCT05880355 | Early Phase 1 (Phase 1) | Jan 1, 2024 | University of Virginia |
| NCT06047262 | Phase 2 | Nov 30, 2023 | Government of Switzerland, Olatec Industries LLC, University of Basel |
| NCT05658575 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2022 | Olatec Industries LLC |
| NCT04971499 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2021 | Duke University, Merck, Olatec Industries LLC |
| NCT04540120 | Phase 2 | Sep 25, 2020 | CTI Clinical Trial and Consulting Services, Olatec Industries LLC |
| NCT03534297 | Phase 1 | May 16, 2018 | Olatec Industries LLC |
| NCT03595371 | Phase 2 | May 15, 2018 | Olatec Industries LLC, Radboud University |
| NCT02134964 | Phase 1 | Jun 1, 2014 | J&S Studies Inc., Olatec Industries LLC |
| NCT02104050 | Phase 2 | Apr 1, 2014 | Cu-Tech, Olatec Industries LLC |
| NCT01768975 | Phase 2 | Jan 1, 2013 | Avail Clinical Research, MRA Clinical Research, Olatec Industries LLC, Wake Research Associates |
| NCT01636141 | Phase 1 | Jun 1, 2012 | J&S Studies Inc., Olatec Industries LLC |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Olatec Industries LLC | For profit | 11 | 8 | 3 | 2012 |
| J&S Studies Inc. | For profit | 2 | 0 | 1 | 2012 |
| Avail Clinical Research | For profit | 1 | 0 | 1 | 2013 |
| CTI Clinical Trial and Consulting Services | For profit | 1 | 0 | 1 | 2020 |
| Cure Parkinson's Trust | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Cu-Tech | For profit | 1 | 0 | 1 | 2014 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Government of Switzerland | Government | 1 | 0 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| MRA Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Cambridge | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Van Andel Research Institute | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Wake Research Associates | For profit | 1 | 0 | 1 | 2013 |
16 organizations
Page 1 / 1